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Abstract
Objective
To evaluate the appropriateness of follow-up with only non-enhanced CT (NECT) in
patients with gastrointestinal cancer.
Subjects and Methods
This retrospective study included 323 patients with colorectal and gastric cancer who under-
went two consecutive CT examinations (CT1 and CT2), including non-contrast and portal
venous phase CT images, with an interval of 1 year. Patients were divided into 2 groups:
Group A included patients with no hepatic metastasis on CT1 and with or without newly
developed metastasis on CT2 to evaluate the diagnostic performance of NECT for detecting
newly developed hepatic metastasis; Group B included patients with known hepatic metas-
tasis both on CT1 and CT2 to evaluate the accuracy of NECT for the assessment of hepatic
metastasis based on RECIST criteria (version 1.1). Contrast-enhanced CT (CECT) images
were considered as reference standards.
Results
Group A included 172 patients (M:F = 107:65; mean age, 62.6 years). Among them,
57 patients had 95 metastases (mean size, 2.2 ± 1.3 cm). Per patient and per lesion sensi-
tivity for diagnosing newly developed hepatic metastasis was 56.1–66.7% and 52.6–56.8%,
respectively. In terms of small metastases (<1.5 cm), per lesion sensitivity was significantly
decreased to 28.1–34.4% (P < 0.05). Metastasis size measurements were significantly
smaller on NECT (P < 0.001) compared with reference standards. In Group B, the accuracy
of response evaluation based on RECIST criteria was 65.6–72.2%.
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Conclusions
NECT showed inadequate diagnostic performances in both detecting newly developed
hepatic metastasis and evaluating the response of hepatic metastasis based on RECIST
criteria.
Introduction
The liver is one of the most common sites of metastasis from extrahepatic neoplasms because
of high blood flow from the dual arterial and portal venous systems, and because it has a micro-
scopic structure that is conducive to the lodgment of circulating tumor cells and a microscopic
environment that favors the rapid growth of established tumor cells [1]. Early detection of
hepatic metastasis or accurate evaluation of preexisting hepatic metastasis is essential to make
treatment plans and to predict prognosis [2]. Contrast-enhanced computed tomography
(CECT) is widely used as the primary imaging modality for the evaluation of hepatic metasta-
sis, and overall sensitivity has been reported as approximately 72–83% with recent multi-detec-
tor CT systems [3,4].
Because most hepatic metastatic lesions, including those from colorectal and gastric cancer,
are hypovascular compared with adjacent normal liver parenchyma, they are usually evaluated
in the portal venous phase (PVP) in which the liver parenchyma shows peak enhancement,
resulting in maximization of tumor-to-liver contrast differences [5,6]. However, NECT is fre-
quently performed without administration of contrast media (CM) in patients with impaired
renal function, who are vulnerable to contrast-induced nephropathy (CIN). Because develop-
ment of CIN increases in-hospital mortality up to 20% and is also a predisposing factor in the
long-term loss of kidney function [7], hesitation about the use of iodinated CM in patients with
impaired renal function is understandable. Alternative imaging modalities can be used, such as
non-contrast magnetic resonance imaging (MRI) and ultrasound (US), and 18F-FDG PET in
these patients. However, limited accessibility, expense, longer scanning times of MRI and
18F-FDG PET, and lower sensitivity and operator dependency of US limit the general use or
entire substitution of non-contrast MRI or US in the diagnosis of hepatic metastasis. Recently,
contrast-enhanced US (CEUS) proved to be useful in the evaluation of hepatic metastases with-
out nephrotoxicity [8]. However, CEUS is also operator dependent, needs dedicated equipment
and has additional cost. Furthermore, CEUS has not been approved yet for the diagnosis of
hepatic metastasis in some countries.
A prior study [9] reported that the diagnostic results of NECT and CECT regarding the sta-
tus of liver metastasis concurred in 71% of cases. However, this study was performed before the
era of multi-detector CT or the establishment of modern injection protocols for CM. Accord-
ing to the recent American College of Radiology (ACR) Appropriateness Criteria, NECT is
usually not appropriate as a surveillance tool following treatment of the primary tumor but can
be potentially indicated if patients cannot receive CM [6]. RECIST 1.1 criteria state that the
appropriateness of NECT in the evaluation of patients who cannot receive CM should be care-
fully discussed with a radiologist on the basis of the tumor type and anatomic location of the
disease, either prior to enrollment or after obtaining baseline CECT. Considering the rapidly
increasing prevalence of chronic renal disease in the present aging society, the diagnostic per-
formance of NECT for the evaluation of hepatic metastasis should be reevaluated as more and
more patients undergo MDCT. Hence, the purpose of this study was to evaluate the appropri-
ateness of follow-up with only NECT in patients with gastrointestinal cancer.
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Materials and Methods
The institutional review board of our institution (Yonsei University College of Medicine)
approved this retrospective study and informed consent was waived. Patients’ information was
anonymized and de-identified prior to analysis.
Study Population
The inclusion criteria were as follows: 1) patients, including those who had and had not under-
gone surgery, with histologically proven colorectal cancer or gastric cancer; 2) patients with
abdominal CECT images including non-contrast images and portal venous phase images
(CT2); 3) patients who had undergone regular follow-up at our hospital for at least 1 year
before and after CT2 and had prior CT (CT1) that had been performed within the previous
12 months. Patients who had undergone local treatment of the liver metastasis between the
two CT scans, such as radiofrequency ablation (RFA) or trans-arterial chemoembolization
(TACE), were excluded. Patients were divided into 2 groups: Group A and Group B. Group A
included both patients with newly developed hepatic metastasis on CT2 that did not present
on CT1 and patients without hepatic metastasis at both CT1 and CT2 for the evaluation of
the diagnostic performance of NECT for detecting newly developed hepatic metastasis;
Group B included patients with known hepatic metastasis on CT1 for the evaluation of the
diagnostic performance of NECT according to the RECIST 1.1 criteria [10]. Among patients
who belonged to Group B, patients who did not have target lesions in the liver (i.e., all hepatic
metastatic lesions were<10 mm) were additionally excluded.
Imaging Technique
CT scans were performed with multi-detector CT scanners (Somatom Sensation 64 or Defini-
tion Flash; Siemens Medical Solutions, Forchhein, Germany). A non-contrast image was
obtained before administration of CM. Then, CM was injected by power injector via the ante-
cubital vein at the rate of 2 mL/kg over 30 seconds. Using a bolus tracking technique, PVP was
obtained 55 seconds after the Hounsfield unit (HU) value of the abdominal aorta had increased
by 100 HU compared with baseline or 30 seconds after the end of the late arterial phase (LAP).
CT parameters were as follows: 0.5-second rotation time; 120 kV; reference mAs, 240 mAs
with automated tube current modulation; beam collimation, 0.6 mm; beam pitch, 1; and 3 mm
slice thickness.
Imaging Analysis
Two experienced abdominal radiologists (M.J.P with 4 years’ and Y.E.C with 7 years’ experi-
ence in abdominal imaging) independently reviewed NECT images of Group A (session 1) and
B (session 2) in separate sessions. The reviewers knew that patients in Group A did not have
metastasis on CT1 regardless of there being newly developed metastasis on CT2 and that
patients in Group B already had liver metastasis on CT1, but they were not aware of any other
clinical information. In the first session, the reviewers were asked whether there was newly
developed metastasis on CT2. If there was newly developed metastasis, the reviewers were
asked to determine the locations of each metastatic lesion and the largest diameter of each
lesion with measurements going up to five lesions in order of increasing size. Then, the review-
ers were asked to grade the confidence level of the lesion on a five-point scale: 1, very unlikely
metastasis; 2, unlikely metastasis; 3, likely metastasis; 4, very likely metastasis; and 5, definitely
metastasis [11]. Lesions with confidence levels of 3, 4, or 5 were regarded as metastases. In
Group B, the reviewers were asked to measure the two largest liver metastases (as target lesions)
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in both the prior and the present CT images and determine response to chemotherapy based
on the RECIST 1.1 criteria [10] as follows: Complete Response (CR), disappearance of all target
lesions; Partial Response (PR), at least a 30% decrease in the sum of the diameters of the target
lesions; Progressive Disease (PD), at least a 20% increase in the sum of the diameters of the tar-
get lesions or the appearance of one or more new lesions; Stable Disease (SD), neither sufficient
shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Reference Standard
In Group A, all imaging modality findings, laboratory results, and clinical diagnoses were care-
fully reviewed at least 1 year before and after CT2 to determine the presence or absence of
hepatic metastasis at CT2. In Group B, the largest two lesions were measured in HVP images
both on CT1 and CT2, and the sum of the two measurements was calculated. Then, response
was evaluated on the basis of RECIST 1.1 criteria [10]. All analyses of reference standards were
performed by two experienced radiologists (M.J.K with 25 years’ and M.S.P with 15 years’
experience in abdominal radiology) who did not participate in the image analysis of the NECT
images.
Statistical Analysis
Diagnostic performances were assessed by frequency table and GEE approach. Tumor size
according to the reference standard and reviewers’measurement was compared by paired t-
test. Interobserver agreement was evaluated by means of Cohen’s κ statistic. Degree of agree-
ment was considered almost perfect, substantial, moderate, fair, and slight according to κ val-
ues between 0.81 and 1.00, between 0.61 and 0.80, between 0.41 and 0.60, between 0.21 and
0.40, and between 0.00 and 0.20.[12] All statistical analysis was performed by a biostatistician
(H.S.L) using SAS (version 9.2; SAS Inc., Cary, NC, USA). P< 0.05 was considered statistically
significant.
Results
Patients
Through the careful review of medical records, 705 patients were identified from February
2005 through February 2012. Among them, 364 patients were excluded after review of CT
images because no CT1 images were available within the preceding year, and 9 patients were
excluded because TACE or RFA was performed between CT1 and CT2. Among the remaining
331 patients, 172 patients (107 men and 65 women; mean age, 62.6 years; age range, 33–85
years) were classified as Group A. In Group A, 57 patients had newly developed metastasis at
CT2. Because an additional 9 patients were excluded because of the absence of target lesions in
the liver, 151 of 160 patients were finally included in Group B (105 men and 46 women; mean
age, 63.4 years; age range, 35–82 years) (Fig 1).
Imaging Analysis
In Group A, there were 95 metastases (mean size = 21.7 ± 13.3 mm) in 57 patients. In per
patient analysis of Group A, sensitivity and specificity was 56.1% and 92.2% for reviewer 1 and
66.7% and 98.3% for reviewer 2, respectively (Table 1). There was no statistically significant dif-
ference in sensitivity and specificity between the two reviewers (P> 0.05). Interobserver agree-
ment between reviewers was substantial (κ = 0.661, 95% CI: 0.528–0.794). In terms of per
lesion analysis, sensitivity was 52.6% for reviewer 1 and 56.8% for reviewer 2. Interobserver
agreement was also substantial (κ = 0.606, 95% CI: 0.510–0.702) (Table 2). Among 95 newly
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developed metastases, 32 nodules were less than 15 mm in size. Diagnostic performance for
smaller lesions less than 15 mm was significantly lower than that for all lesions with both
reviewers (Table 2) (Fig 2). In terms of size measurement, size of hepatic metastatic lesions
measured by each of the reviewers was significantly smaller than that of the reference standard
both for all lesions and for lesions less than 15 mm (Table 3).
In Group B, the accuracy of response evaluation was 72.2%, for reviewer 1 and 65.6% for
reviewer 2 (Table 4) (Fig 3). There was no significant difference in diagnostic accuracy between
the two reviewers, but there was a tendency toward overdiagnosis with reviewer 2 (Table 4).
Interobserver agreement was moderate (κ = 0.591, 95% CI: 0.475–0.707).
Discussion
Our results revealed that the diagnostic accuracy of NECT for the detection of newly developed
hepatic metastasis in patients with colorectal and gastric cancer was 56.1–66.7% in per patient
analysis and 52.6–56.8% in per lesion analysis. Per lesion diagnostic accuracy decreased signifi-
cantly to 28.1–34.4% in the diagnosis of small metastatic lesions less than 1.5 cm in size. Fur-
thermore, metastasis size measurements were significantly smaller on NECT compared with
the reference standard CECT. In terms of diagnostic performance for evaluating treatment
response based on RECIST 1.1 criteria, only 65.6–72.2% of patients were assessed correctly on
NECT.
Because of the inherently low contrast resolution of the liver, optimal contrast enhancement
is essential for the accurate diagnosis of focal hepatic lesions, and according to previous studies,
at least 50 HU of hepatic enhancement is required to obtain high diagnostic quality hepatic CT
images [13,14]. Although prior study reported that there was no significant difference in the
Fig 1. Flow chart of patients’ inclusion and subgrouping.
doi:10.1371/journal.pone.0134133.g001
Table 1. Per patient analysis of diagnostic performance in detection of newly developed hepatic metastasis (Group A).
Per patient SEN (95% CI) SPE (95% CI) ACC (95% CI) PPV (95% CI) NPV (95% CI)
Reviewer 1 56.1 (43.3–69.0) 92.2 (87.3–97.1) 80.2 (74.1–86.2) 78 (65.4–90.7) 80.9 (74.2–87.6)
Reviewer 2 66.7 (54.4–78.9) 98.3 (95.9–100.7) 87.8 (82.9–92.7) 95 (88.2–101.8) 85.6 (79.6–91.6)
P value 0.052 0.052 0.004 0.010 0.011
Note: Numbers in parentheses are 95% conﬁdence intervals.
doi:10.1371/journal.pone.0134133.t001
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assessment of focal hepatic lesions between NECT and CECT [15], a more recent study
reported that PVP showed better diagnostic performance than LAP or NECT; 85% of liver
metastases were detected on PVP whereas only 61% were detected on NECT, and there was no
Table 2. Per lesion analysis of diagnostic performance in detection of newly developed hepatic metastasis (Group A).
SEN (95% CI) SPE (95% CI) ACC (95% CI) PPV (95% CI) NPV (95% CI)
Reviewer 1 All lesions 52.6 (42.6–62.7) 97.5 (96.6–98.4) 93.9 (92.6–95.3) 64.1 (53.5–74.7) 96 (94.9–97.1)
Lesions <15 mm (n = 32) 34.4 (17.9–50.8) 97.5 (96.6–98.4) 95.7 (94.5–96.9) 28.2 (14.1–42.3) 98.1 (97.3–98.9)
P value 0.015 >0.999 <0.001 <0.001 <0.001
Reviewer 2 All lesions 56.8 (46.9–66.8) 98.7 (98.1–99.4) 95.4 (94.3–96.6) 79.4 (69.8–89.0) 96.4 (95.3–97.5)
Lesions <15 mm 28.1 (12.5–43.7) 98.7 (98.1–99.4) 96.8 (95.7–97.8) 39.1 (19.2–59.1) 97.9 (97.1–98.8)
P value <0.001 >0.999 <0.001 <0.001 <0.001
Note: Numbers in parentheses are 95% conﬁdence intervals.
doi:10.1371/journal.pone.0134133.t002
Fig 2. Seventy-year-old womanwho underwent right hemicolectomy and right hemihepatectomy because transverse colon cancer with liver
metastasis. (A, B) On follow-up CT, two newly developed metastases are seen in the remaining left lobe of the liver (arrows). (c, d) On non-enhanced CT
images, low attenuating lesions were suspected at the same locations as those on contrast-enhanced CT, but neither of the reviewers could detect these
lesions.
doi:10.1371/journal.pone.0134133.g002
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patient in whom all liver metastatic lesions were missed on PVP [16]. Our study showed simi-
lar results in that approximately half of the metastatic lesions and only about one-third of the
metastatic lesions less than 1.5 cm in size were diagnosed on NECT. Based on these results, the
diagnostic performance of NECT is inadequate for the detection of newly developed liver meta-
static lesions, particularly small lesions. Hence, follow-up in patients who may develop new
liver metastatic lesions with NECT might be inappropriate.
Nazarian et al [17] demonstrated that the sizes of hepatic metastatic lesions from colorectal
cancer measured on precontrast images were significantly greater than those measured on
postcontrast images for all lesion sizes. Because CM gradually diffuses into the extracellular
space (ECS) of metastatic lesions after CM administration, the peripheral portion of the lesions
might have presented with isoattenuation compared with the adjacent liver parenchyma,
resulting in exclusion from size measurement [18,19]. In a previous study, spiral CT was used
and whole liver scanning might have taken 25–30 seconds to complete [17]. Hence, postcon-
trast images might have been obtained closer to the equilibrium phase than the PVP, at least
for part of the liver, resulting in more diffusion of CM into the ECS and smaller measured sizes
of lesions on postcontrast images compared with precontrast images. In contrast, modern
MDCT was used in our study, and the whole liver could be scanned in about 5 seconds. This
enabled all images of the liver to be acquired within the PVP; thus, maximal CNR of hypovas-
cular metastasis was obtained and lesion size could be measured before CM diffused into the
ECS of hepatic metastasis. Both in lesions of all sizes and lesions less than 1.5 cm, the number
of lesions was underestimated with NECT in our study. An explanation for this finding may be
that low contrast resolution is inferior in NECT compared with CECT. Thus, in the study
images, the central necrotic area—but not the peripheral viable portion—of the tumor could be
differentiated from adjacent normal liver parenchyma, resulting in miscalculations of the lesion
size on NECT.
In our study, 65.6–72.2% of patients were accurately assessed using RECIST 1.1 criteria dur-
ing the follow-up of liver metastasis. This result was comparable with a previous study that
Table 3. Comparison of size of the metastatic nodules in NECT and the reference standard.
Size
(mean ± SD)
P value (between reference standard and
reviewers)
P value (between
reviewers)
All lesions (n = 95)
Reference
standard
21.7 ± 13.3
Reviewer 1 12.8 ± 15.8 <0.001
Reviewer 2 16.1 ± 18.1 <0.001 0.374
Lesions <15 mm
(n = 32)
Reference
standard
10.4 ± 2.3
Reviewer 1 6 ± 9.6 <0.001
Reviewer 2 4.3 ± 7.3 <0.001 0.423
doi:10.1371/journal.pone.0134133.t003
Table 4. Accuracy of response evaluation based on the RECIST 1.1 criteria.
Accurate diagnosis (95% CI) Underdiagnosis (95% CI) Overdiagnosis (95% CI)
Reviewer 1 72.2 (65.0–79.3) 18.5 (12.3–24.7) 9.3 (4.6–13.9)
Reviewer 2 65.6 (58.0–73.1) 15.9 (10.1–21.7) 18.5 (12.3–24.7)
P value 0.074 0.316 <0.001
Note: Numbers in parentheses are 95% conﬁdence intervals.
doi:10.1371/journal.pone.0134133.t004
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revealed approximately 71% of patients showed concordant evaluation results between NECT
and CECT [9]. These findings imply that overestimation or underestimation of treatment
response may occur in one-third of patients, in whom alternative treatment options may not
be considered or may unnecessarily be used. RECIST 1.1 criteria suggest that an optimal and
consistent injection protocol of CM is important to accurately assess patients. If the adminis-
tration of iodinated CM is contraindicated, an alternative imaging modality, such as NECT or
MRI (with or without contrast enhancement), should be selected depending on the tumor type
and anatomical location of each patient [10]. Based on our results, evaluation of metastasis in
the liver with NECT might be inappropriate.
Ultrasound has been and is still widely used as a follow-up imaging modality because it is
readily available and harmless to patients. However, sensitivity in the detection of liver metas-
tasis was only about 40–55% with conventional US [3,20]. This result was probably due to
operator dependency and possible blind spots due to lung, bowel, or patient obesity. Hence, US
is not suitable as a sole follow-up imaging modality in patients with possible liver metastasis.
Contrast-enhanced US is a possible alternative tool, and has shown similar diagnostic
Fig 3. Seventy-two-year-old man who had known liver metastasis from gastric cancer. a. On the portal venous phase, hepatic metastasis is seen in
segment 4 of the liver. b. The size of the lesion appears similar in the non-enhanced CT image. This lesion was measured as 30 mm both in the contrast-
enhanced CT (a) and non-enhanced CT (b) images. (c, d) On follow-up CT after 3 months, the lesion had increased in size. It was measured as 47 mm (57%
interval increase) on contrast-enhanced CT, which suggested progression of disease (c). However, on non-enhanced CT, the mass was measured as 32
mm (7% interval increase), which suggested stable disease.
doi:10.1371/journal.pone.0134133.g003
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performance to CECT [20]. However, accessibility is limited because US CM does not have
worldwide approval and requires dedicated software. Contrast-enhanced MRI has shown
excellent diagnostic performance for liver metastasis with a sensitivity of about 76–88% [3,21].
However, patients with decreased renal function are considered to have a relative contraindica-
tion for contrast enhanced MRI because of the possibility of nephrogenic systemic fibrosis
[22]. Although non-contrast MRI showed similar sensitivity to contrast-enhanced MRI in a
prior meta-analysis [21], contrast enhancement is considered important both for detecting
metastasis and, in particular, for characterizing focal liver lesions [6]. Furthermore, the current
high cost, long examination time, and variable availability globally of MRI hinder its use widely
as a first-line tool for the assessment of liver metastasis [6,10]. 18F-FDG PET can be another
choice for the evaluation of liver metastasis without iodine contrast media. Recent meta-analy-
sis demonstrates that 18F-FDG PET shows good accuracy for the detection of liver metastasis
and can prevent unnecessary surgery [23,24]. However, the sensitivity of PET/CT markedly
decreased after chemotherapy and many colorectal cancer patients with liver metastasis under-
went chemotherapy before or after surgery, hence PET/CT could not completely replace con-
trast enhanced CT or MR [25].
This study has several limitations. First, this study was retrospective. Hence, the characteris-
tics of the patients were heterogeneous, i.e., patients had different stages of gastric or colorectal
cancer and underwent different treatments, and CT was performed at different intervals. How-
ever, we aimed to evaluate the diagnostic performance of NECT in the detection and evaluation
of liver metastasis, and heterogeneity of patient characteristics might not have significantly
influenced results but rather reflected actual clinical situations. Second, hepatic metastasis was
not confirmed histologically. However, two experienced radiologists reviewed all imaging stud-
ies, clinical information, and laboratory results obtained over a follow-up period of at least 1
year to generate the reference standards, and we considered this sufficiently accurate for the
diagnosis and evaluation of hepatic metastasis. Third, metastasis other than liver metastasis
was not evaluated. Considering that the liver is the most common site of metastasis from gas-
trointestinal cancer and only about 23% of patients with liver metastasis have metastasis to
other organs [26], evaluation of liver metastasis was considered critical in the overall assess-
ment of disease status. However, future study is warranted involving the whole abdomen or
body.
In conclusion, NECT showed inadequate diagnostic performances in both the detection of
newly developed hepatic metastasis and the evaluation of the response of hepatic metastasis
based on RECIST criteria in patients with gastric and colorectal cancer. Hence, contrast-
enhanced CT with proper preparations or alternative imaging modalities such as MRI and US
with/without contrast enhancement should be considered, even in patients with decreased
renal function or hypersensitivity to iodinated CM.
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